Cortex Sells 13.75 Million Shares in Offering
- Share via
IRVINE — Cortex Pharmaceuticals Inc. said Thursday that it has sold 13.75 million shares of newly issued common stock at $1 a share to institutional and individual investors.
Proceeds from the offering will be used to fund research and development, as well as for general corporate purposes. The transaction was arranged by Vector Securities International Inc.
Founded in 1987, the Irvine company develops drugs for treating age-related neurological diseases.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
